CRNX
MaterialsCrinetics Pharmaceuticals Inc
Live · NASDAQ · May 9, Close
What's Moving CRNX Today?
No stock-specific AI insight has been generated for CRNX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
CRNX News
20 articles- Crinetics (CRNX) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Crinetics Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- Crinetics Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- The Bull Case For Crinetics Pharmaceuticals (CRNX) Could Change Following EU Nod For Oral Acromegaly Drug PALSONIFYYahoo Finance·May 4, 2026
- Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 4, 2026
- Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma StockYahoo Finance·May 2, 2026
- Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out forYahoo Finance·Apr 30, 2026
- Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is WhyYahoo Finance·Apr 29, 2026
- Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in AdultsYahoo Finance·Apr 27, 2026
- Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass EstimatesYahoo Finance·Apr 22, 2026
- Neutrolis Appoints Caren Deardorf as Chief Business & Strategy OfficerGlobeNewswire Inc.·Apr 15, 2026
- Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 8, 2026
- Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters MoreMotley Fool·Mar 28, 2026
- Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in AcromegalyYahoo Finance·Mar 26, 2026
- Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside PotentialYahoo Finance·Mar 14, 2026
- This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 BreakthroughMotley Fool·Mar 13, 2026
- Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should KnowMotley Fool·Mar 13, 2026
- Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA FilingsMotley Fool·Mar 13, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.